Cargando…

Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs

Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive approach to determine biomarkers from body fluids, such as blood, urine, sputum, and saliva. Tumor cells release cfD...

Descripción completa

Detalles Bibliográficos
Autores principales: Casagrande, Giovanna Maria Stanfoca, Silva, Marcela de Oliveira, Reis, Rui Manuel, Leal, Letícia Ferro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917347/
https://www.ncbi.nlm.nih.gov/pubmed/36768828
http://dx.doi.org/10.3390/ijms24032505
_version_ 1784886343907672064
author Casagrande, Giovanna Maria Stanfoca
Silva, Marcela de Oliveira
Reis, Rui Manuel
Leal, Letícia Ferro
author_facet Casagrande, Giovanna Maria Stanfoca
Silva, Marcela de Oliveira
Reis, Rui Manuel
Leal, Letícia Ferro
author_sort Casagrande, Giovanna Maria Stanfoca
collection PubMed
description Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive approach to determine biomarkers from body fluids, such as blood, urine, sputum, and saliva. Tumor cells release cfDNA, ctDNA, exosomes, miRNAs, circRNAs, CTCs, and DNA methylated fragments, among others, which can be successfully used as biomarkers for diagnosis, prognosis, and prediction of treatment response. Predictive biomarkers are well-established for managing lung cancer, and liquid biopsy options have emerged in the last few years. Currently, detecting EGFR p.(Tyr790Met) mutation in plasma samples from lung cancer patients has been used for predicting response and monitoring tyrosine kinase inhibitors (TKi)-treated patients with lung cancer. In addition, many efforts continue to bring more sensitive technologies to improve the detection of clinically relevant biomarkers for lung cancer. Moreover, liquid biopsy can dramatically decrease the turnaround time for laboratory reports, accelerating the beginning of treatment and improving the overall survival of lung cancer patients. Herein, we summarized all available and emerging approaches of liquid biopsy—techniques, molecules, and sample type—for lung cancer.
format Online
Article
Text
id pubmed-9917347
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99173472023-02-11 Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs Casagrande, Giovanna Maria Stanfoca Silva, Marcela de Oliveira Reis, Rui Manuel Leal, Letícia Ferro Int J Mol Sci Review Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive approach to determine biomarkers from body fluids, such as blood, urine, sputum, and saliva. Tumor cells release cfDNA, ctDNA, exosomes, miRNAs, circRNAs, CTCs, and DNA methylated fragments, among others, which can be successfully used as biomarkers for diagnosis, prognosis, and prediction of treatment response. Predictive biomarkers are well-established for managing lung cancer, and liquid biopsy options have emerged in the last few years. Currently, detecting EGFR p.(Tyr790Met) mutation in plasma samples from lung cancer patients has been used for predicting response and monitoring tyrosine kinase inhibitors (TKi)-treated patients with lung cancer. In addition, many efforts continue to bring more sensitive technologies to improve the detection of clinically relevant biomarkers for lung cancer. Moreover, liquid biopsy can dramatically decrease the turnaround time for laboratory reports, accelerating the beginning of treatment and improving the overall survival of lung cancer patients. Herein, we summarized all available and emerging approaches of liquid biopsy—techniques, molecules, and sample type—for lung cancer. MDPI 2023-01-28 /pmc/articles/PMC9917347/ /pubmed/36768828 http://dx.doi.org/10.3390/ijms24032505 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Casagrande, Giovanna Maria Stanfoca
Silva, Marcela de Oliveira
Reis, Rui Manuel
Leal, Letícia Ferro
Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title_full Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title_fullStr Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title_full_unstemmed Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title_short Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
title_sort liquid biopsy for lung cancer: up-to-date and perspectives for screening programs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917347/
https://www.ncbi.nlm.nih.gov/pubmed/36768828
http://dx.doi.org/10.3390/ijms24032505
work_keys_str_mv AT casagrandegiovannamariastanfoca liquidbiopsyforlungcanceruptodateandperspectivesforscreeningprograms
AT silvamarceladeoliveira liquidbiopsyforlungcanceruptodateandperspectivesforscreeningprograms
AT reisruimanuel liquidbiopsyforlungcanceruptodateandperspectivesforscreeningprograms
AT lealleticiaferro liquidbiopsyforlungcanceruptodateandperspectivesforscreeningprograms